MENOPAUSAL INSOMNIA · White paper
Menopausal Insomnia Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About menopausal insomnia — and why its trials are hard
Menopausal insomnia refers to difficulty initiating or maintaining sleep, early awakening, and poor sleep quality during the perimenopausal, menopausal, and postmenopausal transition, affecting an estimated 40-60% of menopausal women. It is driven largely by declining estrogen and progesterone, which disrupt thermoregulation (producing hot flashes and night sweats) and serotonergic/circadian regulation, and is compounded by mood changes, anxiety, and life-stage stressors. Importantly, no drug is FDA-approved specifically for menopausal insomnia; management relies on agents approved for general insomnia (zolpidem), depression used off-label for sleep (trazodone), off-label gabapentin for vasomotor-driven awakenings, and hormone therapy (e.g., Bijuva) approved for vasomotor symptoms rather than insomnia per se. Cognitive behavioral therapy for insomnia (CBT-I) is first-line. Clinical trials are complicated by fluctuating hormone levels across menopausal stages, high placebo response, and inconsistency between subjective and objective (actigraphy/polysomnography) sleep measures, underscoring the need for stratified enrollment and combined endpoints.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Zolpidem (Ambien) | 1992 | GABA-A receptor agonist; approved for short-term insomnia (general), used for menopausal sleep-onset/maintenance difficulty; not menopause-specific | Polysomnography insomnia studies (transient and chronic insomnia) | Sleep latency, sleep duration, number of awakenings | Superior to placebo on sleep latency, duration and awakenings; menopausal-insomnia-specific efficacy (unverified) |
| Trazodone (Desyrel) | 1981 | Serotonin antagonist/reuptake inhibitor; approved for major depressive disorder, widely used off-label for insomnia including in menopause | MDD inpatient/outpatient trials (label); off-label sleep use | Sleep onset and sleep quality (off-label) | Sedative benefit on sleep onset; robust menopausal-insomnia trial magnitude (unverified) |
| Gabapentin (Neurontin) | 1993 | Approved for epilepsy/postherpetic neuralgia; used off-label for menopausal night sweats and associated sleep disruption | Trials of vasomotor symptoms/night sweats (off-label for insomnia) | Reduction in night sweats/hot flashes and nighttime awakenings | Reduces vasomotor symptoms that disrupt sleep; menopausal-insomnia magnitude (unverified) |
| Estradiol/Progesterone (Bijuva) | 2018 | Bioidentical hormone therapy approved for moderate-to-severe vasomotor symptoms due to menopause (not insomnia); may indirectly improve sleep | REPLENISH (NCT01942668) | Frequency and severity of moderate-to-severe vasomotor symptoms | Significant reduction in VMS frequency vs placebo (difference ~ -12.8 at Week 12, p<0.001); sleep endpoints secondary/indirect |
| Fezolinetant (Veozah) | 2023 | NK3 receptor antagonist approved for moderate-to-severe vasomotor symptoms due to menopause; NOT approved for insomnia (clarification) | SKYLIGHT 1/2 | Frequency and severity of vasomotor symptoms (sleep disturbance a secondary/exploratory measure) | Significant VMS reduction vs placebo; any sleep benefit is secondary and not an insomnia indication |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in menopausal insomnia development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Sodium oxybate — NCT00402564 | Trial in menopausal insomnia terminated over safety concerns | CNS-depressant risks (respiratory depression, dependency) and low compliance, especially concerning in menopausal women |
| Melatonin — NCT00232167 | Terminated/failed for limited efficacy in menopausal insomnia | Targets circadian rhythm only; insufficient against multifactorial hormonal and thermoregulatory sleep disruption |
Choosing the right endpoint
Primary endpoints that matter in menopausal insomnia trials
- Sleep onset latency — Time to fall asleep; measured objectively via actigraphy/polysomnography to reduce variability
- Nighttime (WASO) awakenings — Number/duration of awakenings; confounded by hot flashes and hormonal fluctuation
- Sleep efficiency — Ratio of time asleep to time in bed; often paired with CBT-I to manage pre-sleep anxiety
- Total sleep duration — Actigraphy-recorded nightly sleep; individualized targets needed
- Patient-reported sleep quality — Standardized via Pittsburgh Sleep Quality Index (PSQI); combined with objective measures
How iNGENū runs menopausal insomnia trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Menopausal Insomnia clinical trials — FAQs
Is any drug FDA-approved specifically for menopausal insomnia?
Does fezolinetant (Veozah) treat menopausal insomnia?
Why are menopausal insomnia trials difficult to run?
Related
Explore more
Ready to discuss your menopausal insomnia trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal